Cargando…
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
OBJECTIVE: We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS and experimental autoimmune encephalomyelitis (EAE). METHODS: A cross-sectional study of blood samples from 20 GA-treated and 18 untreated patients with MS was performed...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136047/ https://www.ncbi.nlm.nih.gov/pubmed/32184341 http://dx.doi.org/10.1212/NXI.0000000000000698 |
_version_ | 1783518171881275392 |
---|---|
author | Häusler, Darius Hajiyeva, Zivar Traub, Jan W. Zamvil, Scott S. Lalive, Patrice H. Brück, Wolfgang Weber, Martin S. |
author_facet | Häusler, Darius Hajiyeva, Zivar Traub, Jan W. Zamvil, Scott S. Lalive, Patrice H. Brück, Wolfgang Weber, Martin S. |
author_sort | Häusler, Darius |
collection | PubMed |
description | OBJECTIVE: We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS and experimental autoimmune encephalomyelitis (EAE). METHODS: A cross-sectional study of blood samples from 20 GA-treated and 18 untreated patients with MS was performed by flow cytometry; 6 GA-treated patients with MS were analyzed longitudinally. GA-mediated effects on B-cell antigen-presenting function were investigated in EAE, or, alternatively, B cells were treated with GA in vitro using vehicle as a control. RESULTS: In MS, GA diminished transitional B-cell and plasmablast frequency, downregulated CD69, CD25, and CD95 expression, and decreased TNF-α production, whereas IL-10 secretion and MHC Class II expression were increased. In EAE, we observed an equivalent dampening of proinflammatory B-cell properties and an enhanced expression of MHC Class II. When used as antigen-presenting cells for activation of naive T cells, GA-treated B cells promoted development of regulatory T cells, whereas proinflammatory T-cell differentiation was diminished. CONCLUSIONS: GA immune modulates B-cell function in EAE and MS and efficiently interferes with pathogenic B cell–T cell interaction. |
format | Online Article Text |
id | pubmed-7136047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-71360472020-04-17 Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS Häusler, Darius Hajiyeva, Zivar Traub, Jan W. Zamvil, Scott S. Lalive, Patrice H. Brück, Wolfgang Weber, Martin S. Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS and experimental autoimmune encephalomyelitis (EAE). METHODS: A cross-sectional study of blood samples from 20 GA-treated and 18 untreated patients with MS was performed by flow cytometry; 6 GA-treated patients with MS were analyzed longitudinally. GA-mediated effects on B-cell antigen-presenting function were investigated in EAE, or, alternatively, B cells were treated with GA in vitro using vehicle as a control. RESULTS: In MS, GA diminished transitional B-cell and plasmablast frequency, downregulated CD69, CD25, and CD95 expression, and decreased TNF-α production, whereas IL-10 secretion and MHC Class II expression were increased. In EAE, we observed an equivalent dampening of proinflammatory B-cell properties and an enhanced expression of MHC Class II. When used as antigen-presenting cells for activation of naive T cells, GA-treated B cells promoted development of regulatory T cells, whereas proinflammatory T-cell differentiation was diminished. CONCLUSIONS: GA immune modulates B-cell function in EAE and MS and efficiently interferes with pathogenic B cell–T cell interaction. Lippincott Williams & Wilkins 2020-03-17 /pmc/articles/PMC7136047/ /pubmed/32184341 http://dx.doi.org/10.1212/NXI.0000000000000698 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Häusler, Darius Hajiyeva, Zivar Traub, Jan W. Zamvil, Scott S. Lalive, Patrice H. Brück, Wolfgang Weber, Martin S. Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title_full | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title_fullStr | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title_full_unstemmed | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title_short | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS |
title_sort | glatiramer acetate immune modulates b-cell antigen presentation in treatment of ms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136047/ https://www.ncbi.nlm.nih.gov/pubmed/32184341 http://dx.doi.org/10.1212/NXI.0000000000000698 |
work_keys_str_mv | AT hauslerdarius glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT hajiyevazivar glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT traubjanw glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT zamvilscotts glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT lalivepatriceh glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT bruckwolfgang glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms AT webermartins glatirameracetateimmunemodulatesbcellantigenpresentationintreatmentofms |